Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Confident identification of subgroups from SNP testing in RCTs with binary outcomes.

Biometrical journal. Biometrische Zeitschrift - 1 Feb 2022

Wei Yue, Wang Xinjun, Chew Emily Y, Ding Ying

Abstract excerpt

In modern drug development, genotype information becomes more frequently collected in randomized controlled trials (RCTs) for individualized risk prediction and personalized medicine development. Finding single nucleotide polymorphisms (SNPs) that are predictive of differential treatment efficacy, measured by a clinical outcome, is fundamentally different and more challenging than the traditional association test...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genotype
Share to Macular Degeneration
Share to Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Single Nucleotide

Share to Randomized Controlled Trials as Topic

Share to Treatment Outcome

Source

Identifiers

PMID: 33751636
DOI: 10.1002/bimj.202000170

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Confident identification of subgroups from SNP testing in RCTs with binary outcomes.PMID 33751636Read ↗

Selecting causal risk factors from high-throughput experiments using multivariable Mendelian randomizationSemantic proximity Read ↗

Identification of genome-wide SNP-SNP and SNP-clinical Boolean interactions in age-related macular degeneration.Semantic proximity Read ↗

Large-scale genetic analysis of age-related macular degeneration (AMD) drug targets highlights precision therapy opportunities for patients with high polygenic riskSemantic proximity Read ↗

Statistical assessment of biomarker replicability using MAJAR method.Semantic proximity Read ↗

AWOT and CWOT for genotype and genotype-by-treatment interaction joint analysis in pharmacogenetics GWAS.Semantic proximity Read ↗

Genotype-based risk and pharmacogenetic sampling in clinical trials.Semantic proximity Read ↗

Statistical Assessment of Biomarker Replicability using MAJAR MethodSemantic proximity Read ↗

The benefits of using genetic information to design prevention trials.Semantic proximity Read ↗

Genotype distribution-based inference of collective effects in genome-wide association studies: insights to age-related macular degeneration disease mechanism.Semantic proximity Read ↗

Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s diseaseSemantic proximity Read ↗

Application and interpretation of genome-wide association (GWA) studies for informing pharmacogenomic research - examples from the field of age-related macular degeneration.Semantic proximity Read ↗

An in silico framework for evaluating PRS-guided prognostic enrichment in clinical trial designSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.